SWM
IBB icon

SeaCrest Wealth Management’s iShares Biotechnology ETF IBB Stock Holding History

SeaCrest Wealth Management’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$432K Sell
2,271
-31
-1% -$5.33K 0.05% 322
2026
Q1 		$389K Sell
2,302
-33
-1% -$5.64K 0.04% 401
2025
Q4 		$413K Hold
2,335
– – 0.04% 369
2025
Q3 		$355K Sell
2,335
-248
-10% -$33.9K 0.04% 416
2025
Q2 		$327K Sell
2,583
-1,845
-42% -$226K 0.04% 435
2025
Q1 		$566K Buy
4,428
+1,195
+37% +$162K 0.06% 293
2024
Q4 		$427K Sell
3,233
-6,980
-68% -$981K 0.04% 385
2024
Q3 		$1.49M Buy
10,213
+6,850
+204% +$991K 0.16% 123
2024
Q2 		$462K Sell
3,363
-140
-4% -$18.7K 0.05% 339
2024
Q1 		$481K Buy
3,503
+159
+5% +$21.7K 0.06% 320
2023
Q4 		$455K Buy
3,344
+26
+0.8% +$3.17K 0.06% 336
2023
Q3 		$406K Sell
3,318
-165
-5% -$21K 0.05% 359
2023
Q2 		$442K Buy
3,483
+168
+5% +$21.8K 0.06% 353
2023
Q1 		$428K Sell
3,315
-9,265
-74% -$1.21M 0.06% 364
2022
Q4 		$1.65M Buy
12,580
+143
+1% +$18.5K 0.24% 87
2022
Q3 		$1.46M Buy
12,437
+8,539
+219% +$1.06M 0.22% 90
2022
Q2 		$459K Buy
3,898
+235
+6% +$27.9K 0.06% 349
2022
Q1 		$477K Sell
3,663
-20
-0.5% -$2.6K 0.05% 370
2021
Q4 		$562K Buy
3,683
+417
+13% +$64.6K 0.06% 319
2021
Q3 		$528K Buy
3,266
+295
+10% +$49.6K 0.06% 324
2021
Q2 		$486K Buy
2,971
+266
+10% +$41K 0.06% 348
2021
Q1 		$407K Buy
2,705
+295
+12% +$46.9K 0.05% 370
2020
Q4 		$365K Buy
2,410
+211
+10% +$30.2K 0.05% 372
2020
Q3 		$298K Buy
2,199
+90
+4% +$12.2K 0.05% 393
2020
Q2 		$288K Sell
2,109
-99
-4% -$12.6K 0.05% 399
2020
Q1 		$238K Sell
2,208
-151
-6% -$17.4K 0.05% 389
2019
Q4 		$284K Sell
2,359
-86
-4% -$9.6K 0.05% 417
2019
Q3 		$243K Sell
2,445
-2,269
-48% -$238K 0.05% 440
2019
Q2 		$514K Sell
4,714
-4,088
-46% -$435K 0.1% 230
2019
Q1 		$984K Buy
8,802
+1,274
+17% +$140K 0.17% 125
2018
Q4 		$726K Buy
7,528
+9
+0.1% +$955 0.15% 144
2018
Q3 		$917K Hold
7,519
– – 0.16% 130
2018
Q2 		$826K Sell
7,519
-268
-3% -$28.7K 0.15% 137
2018
Q1 		$831K Sell
7,787
-2,831
-27% -$314K 0.15% 134
2017
Q4 		$1.13M Buy
+10,618
New +$1.13M 0.21% 96

Other funds holding IBB

GIC
Generali Investments CEE Prague, Czech Republic $2.11B AUM 25.53% 1-Year Est. Return
IHL
Investment House LLC Redondo Beach, California $1.92B AUM 25.81% 1-Year Est. Return
AP
Appleton Partners Boston, Massachusetts $1.63B AUM 38.57% 1-Year Est. Return
FMI
Factory Mutual Insurance Waltham, Massachusetts $10.6B AUM 34.1% 1-Year Est. Return
CA
Cumberland Advisors Sarasota, Florida $284M AUM 27.11% 1-Year Est. Return
FNFDCM
Folger Nolan Fleming Douglas Capital Management Washington, District of Columbia $1.22B AUM 34.81% 1-Year Est. Return
AC
Apella Capital West Hartford, Connecticut $7.08B AUM 17.38% 1-Year Est. Return
RFA
Reyes Financial Architecture San Diego, California $179M AUM 31.17% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
DC
Davenport & Co Richmond, Virginia $20.4B AUM 18.11% 1-Year Est. Return

SeaCrest Wealth Management's IBB Position: Q2 2026 in Review

SeaCrest Wealth Management reduced its iShares Biotechnology ETF (IBB) stake by 1.3% in Q2 2026, selling an estimated $5.33K and leaving 2,271 shares worth $432K. The position accounts for 0.05% of the portfolio, ranked #322.

SeaCrest Wealth Management first reported a position in IBB in Q4 2017 and has held it in 35 quarters since. The position peaked at $1.65M in Q4 2022. 201 funds tracked by Wall St. Rank hold IBB as of Q2 2026.

  • SeaCrest Wealth Management held 2,271 shares of iShares Biotechnology ETF worth $432K as of Q2 2026.
  • SeaCrest Wealth Management sold 31 iShares Biotechnology ETF shares in Q2 2026, an estimated $5.33K.
  • iShares Biotechnology ETF made up 0.05% of SeaCrest Wealth Management's portfolio in Q2 2026, its #322 holding.
  • SeaCrest Wealth Management first reported a position in iShares Biotechnology ETF in Q4 2017 and has held it in 35 quarters since.
  • SeaCrest Wealth Management's iShares Biotechnology ETF position peaked at $1.65M in Q4 2022.
  • 201 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q2 2026.

Based on SeaCrest Wealth Management's 13F filing for Q2 2026, filed 9 Jul 2026.